News
As second-line therapy for PsA and axSpA, no clear treatment-retention benefit at 3 years was seen when swapping to a bDMARD with another MOA.
With new systemic treatments now available for psoriatic disease, questions remain on the comparable efficacy and safety of these therapies.
Panelists discuss the challenges and evolving landscape of step therapy protocols in hidradenitis suppurativa treatment, emphasizing the impact on patient adherence, the potential benefits of earlier ...
Valley fever cases are on the rise across California, according to public health officials. After a record year in 2024, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results